Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
-SEC.
Stocks · News reference
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases
Lyora Therapeutics, a new biotech company focused on genetic medicines for inherited retinal diseases, launched with $2.5 million in seed funding. The company's lead programs include LYA-101 for retinitis pigmentosa and LYA-102 for Usher Syndrome Type 2, with plans to submit an IND for LYA-101 within 18 months. The company is led by experienced executives from major genetic medicine firms and co-founded by renowned ophthalmology researchers.